Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes

Cheng, Fan‐Tien; Wang, Saprina Ping Hsien; Su, Chio Hao; Tsai, Tsung Liu; Wu, Ping; Shieh, Dar Bin; Chen, Jyh Horng; Hsieh, Patrick C.; Yeh, Chen Sheng

doi:10.1016/j.biomaterials.2008.01.010

Cited by 133 publications

(74 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that PLGA-PEI NPs is a carrier for drug delivery. 17,18 Accordingly, PLGA-PEI-TAX-S3SI was developed to improve cancer treatment. More PLGA-PEIOre TAX NPs were taken up by A549 and A549/T12 cells compared to free Oregon Green paclitaxel.…”

Section: Discussionmentioning

confidence: 99%

“…Synthesizing stabilizer-free and biodegradable PLGA NPs was previously successful when significant amounts of drugs could be encapsulated in PLGA NPs , 100 nm in diameter. 17,18 One advantage of PLGA NPs is that they can be directly coated with cationic polymers, such as polyethylenimine (PEI), enabling them to carry siRNA on their surfaces through electrostatic interactions. 19,20 Therefore, PLGA-PEI NPs could be used as a carrier that integrates anticancer drugs (inner part) and agents to reduce chemoresistance, eg, siRNA (outer layer).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

Cheng

Shieh³

et al. 2012

IJN

131

View full text Add to dashboard Cite

Background: Effective cancer chemotherapy remains an important issue in cancer treatment, and signal transducer and activator of transcription-3 (Stat3) activation leads to cellular resistance of anticancer agents. Polymers are ideal vectors to carry both chemotherapeutics and small interfering ribonucleic acid (siRNA) to enhance antitumor efficacy. In this paper, poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with paclitaxel and Stat3 siRNA were successfully synthesized, and their applications in cancer cells were investigated. Methods: Firstly, paclitaxel was enclosed by PLGA nanoparticles through solvent evaporation. They were then coated with cationic polyethylenimine polymer (PLGA-PEI-TAX), enabling it to carry Stat3 siRNA on its surface through electrostatic interactions (PLGA-PEI-TAX-S3SI). The size, zeta potential, deliver efficacy, and release profile of the PLGA nanocomplexes were characterized in vitro. The cellular uptake, intracellular nanoparticle trajectory, and subsequent cellular events were evaluated after treatment with various PLGA nanocomplexes in human lung cancer A549 cells and A549-derived paclitaxel-resistant A549/T12 cell lines with α-tubulin mutation. Results: A549 and A549/T12 cells contain constitutively activated Stat3, and silencing Stat3 by siRNA made both cancer cells more sensitive to paclitaxel. Therefore, PLGA-PEI-TAX-S3SI was synthesized to test its therapeutic role in A549 and A549/T12 cells. Transmission electron microscopy showed the size of PLGA-PEI-TAX-S3SI to be around 250 nm. PLGA-PEI nanoparticles were nontoxic. PLGA-PEI-TAX was taken up by A549 and A549/T12 cells more than free paclitaxel, and they induced more condensed microtubule bundles and had higher cytotoxicity in these cancer cells. Moreover, the yellowish fluorescence observed in the cytoplasm of the cancer cells indicates that the PLGA-PEI nanoparticles were still simultaneously delivering Oregon Green paclitaxel and cyanine-5-labeled Stat3 siRNA 3 hours after treatment. Furthermore, after the cancer cells were incubated with the synthesized PLGA nanocomplexes, PLGA-PEI-TAX-S3SI suppressed Stat3 expression and induced more cellular apoptosis in A549 and A549/T12 cells compared with PLGA-PEI-TAX. Conclusion:The PLGA-PEI-TAX-S3SI complex provides a new therapeutic strategy to control cancer cell growth.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

Cheng

Shieh³

et al. 2012

IJN

131

View full text Add to dashboard Cite

show abstract

“…Nanoparticle size is significant, not only in determining the release profile and degradation manners, but also in determining the efficacy of the therapeutic agent in terms of tissue penetration and cellular uptake (Gaumet et al, 2008;Dinarvand et al, 2011). Particle size, size distribution and morphology determined by Dynamic light scattering or photon correlation spectroscopy (Govender et al, 1999;Fonseca et al, 2002;Cheng et al, 2008), Scanning electron microscopy (Mu and Feng, 2003;Ricci-Júnior and Marchetti, 2006;Esmaeili et al, 2008b), transmission electron microscopy (Panyam et al, 2003;Mo and Lim, 2005;Yang et al, 2007) and Atomic force microscopy (Ravi Dong and Feng, 2005;Song et al, 2006).…”

Section: Nanoparticle Characterization Techniquesmentioning

confidence: 99%

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Mirakabad

Nejati-Koshki²,

Akbarzadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

411

154

View full text Add to dashboard Cite

“…It is also desirable to maintain a steady rate of infusion of the drug into the tumor to maximize exposure to dividing cells, resulting in tumor regression. 41,48,49 Scanning electron microscopy 28,50,51 Transmission electron microscopy [52][53][54] Atomic force microscopy [55][56][57] …”

Section: Plga Nanoparticles For Drug Delivery To Tumorsmentioning

confidence: 99%

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Dinarvand¹,

Sepehri²,

Manoochehri³

et al. 2011

IJN

396

265

View full text Add to dashboard Cite

The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.

show abstract

Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes

Cited by 133 publications

References 30 publications

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

PLGA-Based Nanoparticles as Cancer Drug Delivery Systems

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

Contact Info

Product

Resources

About